fashion -WSS

fashion

author：knowledge 2025-10-02 22:56:43 - browse：8147

Eli Lilly headquarters — Kristoffer Tripplaar/AP

The drug giant Eli Lilly said Thursday that its diabetes drug Mounjaro helped patients with the condition lose 15.7% of their body weight in a clinical trial, a result that Wall Street analysts expect to pave the way for the therapy’s approval as a weight loss treatment.

Mounjaro is the latest drug in a class known as GLP-1s or incretins — the same class as Novo Nordisk’s Ozempic, which has become a sensation because of its ability to help patients lose weight. Mounjaro has shown the potential to lead to even greater weight loss than Ozempic, and industry experts expect that it will eventually generate many billions of dollars in annual sales. Analysts at SVB Securities projected in December that Mounjaro sales could reach $26.4 billion by 2030.

Eli Lilly on Thursday also announced quarterly earnings of $1.64 per share, adjusted for one-time items, slightly below analyst expectations, on sales of $6.96 billion. Sales were hurt because of a comparison to a year ago, when the company’s Covid-19 monoclonal antibodies were still on the market. Mounjaro sales for the first quarter were $586 million, largely for people with diabetes, compared to an analyst consensus of $433.2 million.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Eli Lilly’s Mounjaro succeeds in second weight

WSS

Physicians and social media: If you see something, say something?

U.K. researchers warn about biases in medical devices, algorithms

Future doctors should be trained to promote social change

Reanimated hearts work just as well for transplants, study finds

Colonoscopy prep: Liquid

Over 1,300 arrested in France in 4th night of protests over fatal police shooting of teen Nahel M.

explore

fashion

entertainment

Drug repurposing or repositioning? The language matters

Novo pauses ads for weight loss drug Wegovy amid demand

In age of alternative facts, a scholarly course on calling out crap

Physicians and social media: If you see something, say something?

Virginia high school admissions case could be legal follow

Intermittent fasting comes with a heart risk? Not so fast

State Dept. review finds Biden bears some blame for Afghanistan failures

Physicians and social media: If you see something, say something?

Trump demands the U.S. pay no more for drugs than other countries … again

Eli Lilly’s Mounjaro succeeds in second weight

focus

Colonoscopy prep: Liquid

Methadone treatment changes are coming. Do they go far enough?

A public health expert passes on football's full body collisions for youths

Mom launches Girl Scout troop for LGBTQ youth in Texas

SCOTUS questions limit to govt efforts to fight misinformation

Argenx readies a blockbuster opportunity with drug for autoimmune disease

Wikipedia

knowledge

Wikipedia

hotspot